Influenza A virus early replication processes

Influenza A virus early replication processes encompass the initial stages of the viral life cycle, including attachment, endocytosis, fusion, uncoating, and the start of viral RNA synthesis (NIH, 2024). These steps are mediated by specific viral proteins: Hemagglutinin (HA) facilitates attachment and membrane fusion; the Matrix protein 2 (M2) ion channel enables uncoating by acidifying the virion interior; and the RNA-dependent RNA polymerase (RdRp) complex initiates transcription and replication (PubMed, 2023). Drugs targeting these processes aim to halt the infection before significant viral progeny are produced (WHO, 2022). For instance, adamantanes (amantadine and rimantadine) block the M2 channel, while newer agents like baloxavir marboxetil inhibit the polymerase's endonuclease activity (ChEMBL). However, the clinical utility of many early-stage inhibitors is limited by the rapid development of viral resistance, particularly in the M2 protein (NIH, 2024).

Other names

Influenza A virus entry and uncoatingEarly stages of influenza A replicationIAV early replicationInfluenza A virus attachment and fusion

Inhibition of viral uncoating via M2 channel blockade, inhibition of viral fusion via hemagglutinin stabilization, and inhibition of viral RNA synthesis via polymerase inhibition.